OR WAIT null SECS
July 15, 2024
PRAC is recommending that patients who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) consider the risk of delayed gastric emptying before undergoing surgery with general anesthesia or deep sedation.
June 24, 2024
This alert follows a similar one from the European Medicines Agency in October 2023 amid a rise in demand for the diabetes medication that, in turn, created a shortage.
June 19, 2024
PRAC is reviewing the risk of secondary malignancies in patients treated with CAR T-cell medicines.
May 23, 2024
The units are being recalled because of incomplete crimp seals and one complaint of a leaking unit.
May 20, 2024
After a review, the agency concluded there was a possible risk of cancer to those exposed to 17-hydroxyprogesterone caproate in the womb.
April 12, 2024
The agency’s risk assessment committee has concluded that available evidence has not been found that supports a causal association between glucagon-like peptide-1 receptor agonists and self-harming thoughts and actions.
March 30, 2024
The company is voluntarily recalling the product for potential super potent bottles due to overfilling.
March 22, 2024
The company is recalling one lot of the product because of the potential presence of silicone particulates.
February 21, 2024
FDA's Drug Safety Priorities FY23 describes the center’s key safety programs and activities involved in promoting and protecting public health.
February 12, 2024
The agency’s safety committee stressed the risk of potential adverse reactions involved with taking Paxlovid (nirmatrelvir, ritonavir) in combination with certain immunosuppressants.